Sichuan Biokin Pharmaceutical Co. Ltd. A
Sichuan Biokin Pharmaceutical Co.,Ltd. engages in the research and development, production, and supply of biomedicine in the fields of antibody drug conjugate, guidance navigation and control, and antibody radionuclide conjugate in China and internationally. It offers anesthesia, parenteral nutrition, anti-infectives, pediatrics, and traditional Chinese medicines. The company was founded in 1996 … Read more
Sichuan Biokin Pharmaceutical Co. Ltd. A (688506) - Total Assets
Latest total assets as of June 2025: CN¥7.18 Billion CNY
Based on the latest financial reports, Sichuan Biokin Pharmaceutical Co. Ltd. A (688506) holds total assets worth CN¥7.18 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sichuan Biokin Pharmaceutical Co. Ltd. A - Total Assets Trend (2021–2024)
This chart illustrates how Sichuan Biokin Pharmaceutical Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sichuan Biokin Pharmaceutical Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Sichuan Biokin Pharmaceutical Co. Ltd. A's total assets of CN¥7.18 Billion consist of 88.4% current assets and 11.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 45.1% |
| Accounts Receivable | CN¥106.72 Million | 1.5% |
| Inventory | CN¥162.19 Million | 2.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥26.68 Million | 0.4% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Sichuan Biokin Pharmaceutical Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sichuan Biokin Pharmaceutical Co. Ltd. A's current assets represent 88.4% of total assets in 2024, an increase from 44.5% in 2021.
- Cash Position: Cash and equivalents constituted 45.1% of total assets in 2024, up from 16.2% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 2.3% of total assets.
Sichuan Biokin Pharmaceutical Co. Ltd. A Competitors by Total Assets
Key competitors of Sichuan Biokin Pharmaceutical Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp Preferred
KO:000105
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
|
Yuyu Pharma
KO:000220
|
Korea | ₩202.42 Billion |
|
Ildong Holdings Co Ltd
KO:000230
|
Korea | ₩813.62 Billion |
Sichuan Biokin Pharmaceutical Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Sichuan Biokin Pharmaceutical Co. Ltd. A generates 0.82x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Sichuan Biokin Pharmaceutical Co. Ltd. A generates $ 51.95 in net profit.
Sichuan Biokin Pharmaceutical Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.66 | 2.97 | 2.97 |
| Quick Ratio | 3.56 | 2.89 | 2.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥4.56 Billion | CN¥ 4.23 Billion | CN¥ 4.23 Billion |
Sichuan Biokin Pharmaceutical Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Sichuan Biokin Pharmaceutical Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.52 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | 400.8% |
| Total Assets | CN¥7.14 Billion |
| Market Capitalization | $2.58 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sichuan Biokin Pharmaceutical Co. Ltd. A's assets below their book value (0.36 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sichuan Biokin Pharmaceutical Co. Ltd. A's assets grew by 400.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sichuan Biokin Pharmaceutical Co. Ltd. A (2021–2024)
The table below shows the annual total assets of Sichuan Biokin Pharmaceutical Co. Ltd. A from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥7.14 Billion | +400.83% |
| 2023-12-31 | CN¥1.43 Billion | -28.44% |
| 2022-12-31 | CN¥1.99 Billion | +109.30% |
| 2021-12-31 | CN¥951.46 Million | -- |